Comparison of Steady-State Pharmacokinetics of Donepezil Transdermal Delivery System with Oral Donepezil

Manuscript Number: 

22-0530R1

Author(s): 
Rene Braeckman, Charles Oh, Pierre N. Tariot

Disclosures

Rene Braeckman

  • Equity:
    Investments in KemPharm, Inc
    Sponsors:
    Employed by KemPharm, Inc

Charles Oh

  • Equity:
    I have stock options in Corium, Inc, which is a privately company that Sponsored the study in the manuscript
    Sponsors:
    I am an employee of Corium, Inc.

Pierre N. Tariot

  • Consulting Fees:
    Consulting fees from Abbvie, AC Immune, Acadia, Biogen, Cortexyme, Eisai, Genentech, Merck, Novo Nordisk and T3D Therapeutics Research support from Abbvie, Biogen, Cortexyme, Genentech, Lilly, Merck, Novo Nordisk, Novartis and Roche
    Equity:
    Investment Interests; Adamas Pharmaceuticals, Inc. (sold stock in December 2020)
    Patents/Royalties
    U.S. Contributor to a patent owned by the University of Rochester - Patent # 11/632,747, “Biomarkers of Neurodegenerative disease.”